News headlines about MannKind (NASDAQ:MNKD) have been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MannKind earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 44.3703297497892 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the headlines that may have effected Accern’s rankings:

MannKind (NASDAQ:MNKD) opened at $3.13 on Monday. MannKind has a fifty-two week low of $0.67 and a fifty-two week high of $6.96. The company has a debt-to-equity ratio of -0.43, a quick ratio of 0.28 and a current ratio of 0.31.

MannKind (NASDAQ:MNKD) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.11). MannKind had a negative return on equity of 24.93% and a negative net margin of 155.83%. The firm had revenue of $2.04 million during the quarter, compared to analysts’ expectations of $2.56 million. During the same quarter in the previous year, the company posted $1.30 earnings per share. MannKind’s revenue for the quarter was down 98.7% compared to the same quarter last year. sell-side analysts predict that MannKind will post -1.13 EPS for the current fiscal year.

MNKD has been the subject of a number of research reports. Zacks Investment Research cut MannKind from a “hold” rating to a “sell” rating in a report on Saturday, August 12th. Maxim Group reiterated a “buy” rating on shares of MannKind in a report on Friday, September 1st. HC Wainwright initiated coverage on MannKind in a report on Tuesday, October 10th. They issued a “buy” rating for the company. ValuEngine cut MannKind from a “hold” rating to a “sell” rating in a report on Wednesday, October 18th. Finally, BidaskClub cut MannKind from a “buy” rating to a “hold” rating in a report on Saturday. Three investment analysts have rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $0.92.

In related news, Director Kent Kresa bought 166,600 shares of the company’s stock in a transaction that occurred on Friday, October 13th. The stock was bought at an average cost of $6.00 per share, for a total transaction of $999,600.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 1.10% of the stock is currently owned by corporate insiders.

WARNING: This report was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/12/04/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-mannkind-mnkd-share-price.html.

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.

Insider Buying and Selling by Quarter for MannKind (NASDAQ:MNKD)

Receive News & Stock Ratings for MannKind Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind Corporation and related stocks with our FREE daily email newsletter.